Skip to main content
Top
Published in: Diabetologia 5/2009

01-05-2009 | Article

Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion

Authors: G. Mingrone, G. Nolfe, G. Castagneto Gissey, A. Iaconelli, L. Leccesi, C. Guidone, G. Nanni, J. J. Holst

Published in: Diabetologia | Issue 5/2009

Login to get access

Abstract

Aims/hypothesis

We tested the hypothesis that the reversibility of insulin resistance and diabetes observed after biliopancreatic diversion (BPD) is related to changes in circadian rhythms of gastrointestinal hormones.

Methods

Ten morbidly obese participants, five with normal glucose tolerance (NGT) and five with type 2 diabetes, were studied before and within 2 weeks after BPD. Within-day variations in glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1) levels were assessed using a single cosinor model. Insulin sensitivity was assessed by euglycaemic–hyperinsulinaemic clamp.

Results

Basal GLP1 relative amplitude (amplitude/mesor × 100) was 25.82–4.06% in NGT; it increased to 41.38–4.32% after BPD but was unchanged in diabetic patients. GLP1 and GIP mesor were shifted in time after surgery in diabetic patients but not in NGT participants. After BPD, the GLP1 AUC significantly increased from 775 ± 94 to 846 ± 161 pmol l−1 min in NGT, whereas GIP AUC decreased significantly from 1,373 ± 565 to 513 ± 186 pmol l−1 min in diabetic patients. Two-way ANOVA showed a strong influence of BPD on both GIP (p = 0.010) and GLP1 AUCs (p = 0.033), which was potentiated by the presence of diabetes, particularly for GIP (BPD × diabetes, p = 0.003). Insulin sensitivity was markedly improved (p < 0.01) in NGT (from 9.14 ± 3.63 to 36.04 ± 8.55 µmol [kg fat-free mass]−1 min−1) and diabetic patients (from 9.49 ± 3.56 to 38.57 ± 4.62 µmol [kg fat-free mass]−1 min−1).

Conclusions/interpretation

An incretin circadian rhythm was shown for the first time in morbid obesity. The effect of BPD on the 24 h pattern of incretin differed between NGT and diabetic patients. GLP1 secretion impairment was reversed in NGT and could not be overcome by surgery in diabetes. On the other hand, GIP secretion was blunted after the operation only in diabetic patients, suggesting a role in insulin resistance and diabetes.
Literature
1.
go back to reference Vilsbøll T, Holst JJ (2004) Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 47:357–366PubMedCrossRef Vilsbøll T, Holst JJ (2004) Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 47:357–366PubMedCrossRef
2.
go back to reference Nauck M, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301–307PubMedCrossRef Nauck M, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301–307PubMedCrossRef
3.
go back to reference Nauck M, Stöckmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46–52PubMedCrossRef Nauck M, Stöckmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46–52PubMedCrossRef
4.
go back to reference Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414:782–787PubMedCrossRef Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414:782–787PubMedCrossRef
5.
go back to reference Leibson CL, Williamson DF, Melton LJ 3rd et al (2001) Temporal trends in BMI among adults with diabetes. Diabetes Care 24:1584–1589PubMedCrossRef Leibson CL, Williamson DF, Melton LJ 3rd et al (2001) Temporal trends in BMI among adults with diabetes. Diabetes Care 24:1584–1589PubMedCrossRef
6.
go back to reference Golay A, Ybarra J (2005) Link between obesity and type 2 diabetes. Best Pract Res Clin Endocrinol Metab 19:649–663PubMedCrossRef Golay A, Ybarra J (2005) Link between obesity and type 2 diabetes. Best Pract Res Clin Endocrinol Metab 19:649–663PubMedCrossRef
7.
go back to reference Muscelli E, Mari A, Casolaro A et al (2008) Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 57:1340–1348PubMedCrossRef Muscelli E, Mari A, Casolaro A et al (2008) Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 57:1340–1348PubMedCrossRef
8.
go back to reference Anderson JW, Grant L, Gotthelf L, Stifler LT (2006) Weight loss and long-term follow-up of severely obese individuals treated with an intense behavioral program. Int J Obes 31:488–493CrossRef Anderson JW, Grant L, Gotthelf L, Stifler LT (2006) Weight loss and long-term follow-up of severely obese individuals treated with an intense behavioral program. Int J Obes 31:488–493CrossRef
9.
go back to reference MacDonald KG, Long SD, Swanson MS et al (1997) The gastric bypass operation reduces the progression and mortality of NIDDM. J Gastrointest Surg 1:213–220PubMedCrossRef MacDonald KG, Long SD, Swanson MS et al (1997) The gastric bypass operation reduces the progression and mortality of NIDDM. J Gastrointest Surg 1:213–220PubMedCrossRef
10.
go back to reference Rubino F, Gagner M, Gentileschi P et al (2004) The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 240:236–242PubMedCrossRef Rubino F, Gagner M, Gentileschi P et al (2004) The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 240:236–242PubMedCrossRef
11.
go back to reference Guidone C, Manco M, Valera-Mora E et al (2006) Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes 55:2025–2031PubMedCrossRef Guidone C, Manco M, Valera-Mora E et al (2006) Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes 55:2025–2031PubMedCrossRef
12.
go back to reference Laferrère B, Teixeira J, McGinty J et al (2008) Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 93:2479–2485PubMedCrossRef Laferrère B, Teixeira J, McGinty J et al (2008) Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 93:2479–2485PubMedCrossRef
13.
go back to reference Laferrère B, Heshka S, Wang K et al (2007) Incretin levels and effect are markedly enhanced 1 month after roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 30:1709–1716PubMedCrossRef Laferrère B, Heshka S, Wang K et al (2007) Incretin levels and effect are markedly enhanced 1 month after roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 30:1709–1716PubMedCrossRef
14.
go back to reference Rodieux F, Giusti V, D’Alessio DA, Suter M, Tappy L (2008) Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity 16:298–305PubMedCrossRef Rodieux F, Giusti V, D’Alessio DA, Suter M, Tappy L (2008) Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity 16:298–305PubMedCrossRef
15.
go back to reference Pories WJ, Albrecht RJ (2001) Etiology of type II diabetes mellitus: role of the foregut. World J Surg 25:527–531PubMedCrossRef Pories WJ, Albrecht RJ (2001) Etiology of type II diabetes mellitus: role of the foregut. World J Surg 25:527–531PubMedCrossRef
16.
go back to reference Mingrone G, DeGaetano A, Greco AV et al (1997) Reversibility of insulin resistance in obese diabetic patients: role of plasma lipids. Diabetologia 40:599–605PubMedCrossRef Mingrone G, DeGaetano A, Greco AV et al (1997) Reversibility of insulin resistance in obese diabetic patients: role of plasma lipids. Diabetologia 40:599–605PubMedCrossRef
17.
go back to reference Camastra S, Manco M, Mari A et al (2007) Beta-cell function in severely obese type 2 diabetic patients: long-term effects of bariatric surgery. Diabetes Care 30:1002–1004PubMedCrossRef Camastra S, Manco M, Mari A et al (2007) Beta-cell function in severely obese type 2 diabetic patients: long-term effects of bariatric surgery. Diabetes Care 30:1002–1004PubMedCrossRef
18.
go back to reference Mari A, Manco M, Guidone C et al (2006) Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: role of insulin sensitivity and beta cell function. Diabetologia 49:2136–2143PubMedCrossRef Mari A, Manco M, Guidone C et al (2006) Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: role of insulin sensitivity and beta cell function. Diabetologia 49:2136–2143PubMedCrossRef
19.
go back to reference DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214–E223PubMed DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214–E223PubMed
20.
go back to reference Krarup T, Madsbad S, Moody AJ et al (1983) Diminished gastric inhibitory polypeptide (GIP) response to a meal in newly diagnosed type I (insulin dependent) diabetics. J Clin Endocrinol Metab 56:1306–1312PubMedCrossRef Krarup T, Madsbad S, Moody AJ et al (1983) Diminished gastric inhibitory polypeptide (GIP) response to a meal in newly diagnosed type I (insulin dependent) diabetics. J Clin Endocrinol Metab 56:1306–1312PubMedCrossRef
21.
go back to reference Ørskov C, Rabenhøj L, Kofod H, Wettergren A, Holst JJ (1994) Production and secretion of amidated and glycine-extended glucagon-like peptide-1 (GLP-1) in man. Diabetes 43:535–539PubMedCrossRef Ørskov C, Rabenhøj L, Kofod H, Wettergren A, Holst JJ (1994) Production and secretion of amidated and glycine-extended glucagon-like peptide-1 (GLP-1) in man. Diabetes 43:535–539PubMedCrossRef
22.
go back to reference Simon C, Brandenberger G (2002) Ultradian oscillations of insulin secretion in humans. Diabetes 51:S258–S261PubMedCrossRef Simon C, Brandenberger G (2002) Ultradian oscillations of insulin secretion in humans. Diabetes 51:S258–S261PubMedCrossRef
23.
go back to reference Flatt PR, Bailey CJ, Kwasowski P, Page T, Marks V (1984) Plasma immunoreactive gastric inhibitory polypeptide in obese hyperglycaemic (ob/ob) mice. J Endocrinol 101:249–256PubMedCrossRef Flatt PR, Bailey CJ, Kwasowski P, Page T, Marks V (1984) Plasma immunoreactive gastric inhibitory polypeptide in obese hyperglycaemic (ob/ob) mice. J Endocrinol 101:249–256PubMedCrossRef
24.
go back to reference Vilsbøll T, Krarup T, Sonne J et al (2003) Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 88:2706–2713PubMedCrossRef Vilsbøll T, Krarup T, Sonne J et al (2003) Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 88:2706–2713PubMedCrossRef
25.
go back to reference McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA, Flatt PR (2007) GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metab 293:E1746–E1755PubMedCrossRef McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA, Flatt PR (2007) GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metab 293:E1746–E1755PubMedCrossRef
26.
go back to reference Gault VA, Irwin N, Green BD et al (2005) Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54:2436–2446PubMedCrossRef Gault VA, Irwin N, Green BD et al (2005) Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54:2436–2446PubMedCrossRef
27.
go back to reference Damholt AB, Kofod H, Buchan AM (1999) Immunocytochemical evidence for a paracrine interaction between GIP and GLP-1-producing cells in canine small intestine. Cell Tissue Res 298:287–293PubMedCrossRef Damholt AB, Kofod H, Buchan AM (1999) Immunocytochemical evidence for a paracrine interaction between GIP and GLP-1-producing cells in canine small intestine. Cell Tissue Res 298:287–293PubMedCrossRef
28.
go back to reference McClean PL, Irwin N, Hunter K, Gault VA, Flatt PR (2008) (Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy. Br J Pharmacol 155:690–701PubMedCrossRef McClean PL, Irwin N, Hunter K, Gault VA, Flatt PR (2008) (Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy. Br J Pharmacol 155:690–701PubMedCrossRef
29.
go back to reference Rubino F (2008) Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care 31:S290–S296PubMedCrossRef Rubino F (2008) Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care 31:S290–S296PubMedCrossRef
Metadata
Title
Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion
Authors
G. Mingrone
G. Nolfe
G. Castagneto Gissey
A. Iaconelli
L. Leccesi
C. Guidone
G. Nanni
J. J. Holst
Publication date
01-05-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 5/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1288-9

Other articles of this Issue 5/2009

Diabetologia 5/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.